NCT00119236View on ClinicalTrials.gov

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2008

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

tanespimycin

DRUG

irinotecan hydrochloride

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00119236 - 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter